Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
1. A method of treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to a nucleic acid encoding a portion of the CA1 region of a mammalian KSR, wherein the oligonucleotide is from 8 to about 50 nucleotides in length, which inhibits the expression of mammalian KSR protein, wherein the cancer is associated with the expression of gf-Ras or heightened expression of Ras.
2. The method of claim 1 , wherein said cancer is selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer.
3. The method of claim 2 , wherein said cancer is pancreatic cancer.
4. The method of claim 2 , wherein said cancer is lung cancer.
5. The method of claim 1 , wherein said oligonucleotide is from 10 to 30 nucleotides in length.
6. The method of claim 1 , wherein said oligonucleotide is from 15 to 25 nucleotides in length.
7. The method of claim 1 , wherein said oligonucleotide is 18 nucleotides in length.
8. The method of claim 1 , wherein said oligonucleotide is labeled with a detectable label.
9. The method of claim 8 , wherein said label is an enzyme, a ligand, a chemical which fluoresces or a radioactive element.
10. The method of claim 1 , wherein said oligonucleotide comprises a modified backbone.
11. The method of claim 10 , wherein said modified backbone is selected from a phosphorothioate, a phosphotriester, a methyl phosphonate, a polyamide, and a morpholino backbone.
12. The method of claim 1 , wherein said oligonucleotide comprises at least one phosphorothioate linkage.
13. The method of claim 1 , wherein said oligonucleotide is an oligodeoxynucleotide.
14. The method of claim 1 , wherein said cancer is colon cancer.
15. The method of claim 1 , wherein said cancer is skin cancer.
16. The method of claim 1 , wherein said cancer is associated with the expression of gf-Ras.
17. A method of conferring radiosensitivity to ionizing radiation in tumor cells in a mammal comprising administering to a mammal a therapeutically effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to a nucleic acid encoding a portion of the CA1 region of a mammalian KSR, wherein the oligonucleotide is from 8 to about 50 nucleotides in length, wherein the oligonucleotide confers radiosensitivity to ionizing radiation in the tumor cells, wherein the tumor is associated with the expression of gf-Ras or heightened expression of Ras.
18. The method of claim 17 wherein the tumor cells are cancer cells selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer.